ClinicalTrials.gg
CompletedNCT07898163Updated Nov 4, 2026

Comparing Cross-Linked and Non-Cross-Linked Hyaluronic Acid for Early Healing After Tooth Extraction

An interventional study of Cross-linked sodium hyaluronate 1% and Non-cross-linked low-molecular-weight hyaluronic acid in Wound Healing After Tooth Extraction, sponsored by Cyprus Health and Social Sciences University. Completed at 1 site in Cyprus. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Cyprus Health and Social Sciences University · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study compares early healing after a non-surgical tooth extraction in adults. Participants are assigned by chance to one of three groups: cross-linked hyaluronic acid placed in the extraction site using a gelatin sponge; non-cross-linked hyaluronic acid placed using a gelatin sponge; or a gelatin sponge alone. The study team measures the wound area using photographs at the time of extraction and on days 3, 7, and 14. A clinician who does not know the assigned group also assesses healing. Participants report their pain and use of pain-relief medicine. The study compares healing among the three groups.

02

Conditions studied

  • Wound Healing After Tooth Extraction
03

In context

Lead sponsor

Cyprus Health and Social Sciences University is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-45 years
  • Systemically healthy
  • Light smokers, instructed to abstain completely from smoking for the first 72 postoperative hours
  • Requiring simple posterior tooth extraction
  • Clinically achievable hemostasis

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases affecting healing
  • Pregnancy or lactation
  • Acute infection at the extraction site
  • Use of anti-inflammatory or drugs
  • Surgical extraction requiring flap elevation or bone removal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Cross-Linked HA + Gelatin Sponge

    Participants receive cross-linked hyaluronic acid delivered via a gelatin sponge after non-surgical tooth extraction.

    Drug: Cross-linked sodium hyaluronate 1% · Device: Gelatin sponge

  • Experimental
    Non-Cross-Linked HA + Gelatin Sponge

    Participants receive non-cross-linked hyaluronic acid delivered via a gelatin sponge after non-surgical tooth extraction.

    Device: Non-cross-linked low-molecular-weight hyaluronic acid · Device: Gelatin sponge

  • Active comparator
    Gelatin Sponge Alone

    Participants receive a gelatin sponge alone after non-surgical tooth extraction.

    Device: Gelatin sponge

Interventions

  • DrugCross-linked sodium hyaluronate 1%

    Cross-linked sodium hyaluronate 1% applied locally to the extraction socket using a gelatin sponge after non-surgical tooth extraction.

  • DeviceNon-cross-linked low-molecular-weight hyaluronic acid

    Non-cross-linked low-molecular-weight hyaluronic acid applied locally to the extraction socket using a gelatin sponge after non-surgical tooth extraction.

  • DeviceGelatin sponge

    Gelatin sponge placed in the extraction socket without hyaluronic acid after non-surgical tooth extraction.

06

What researchers measure

Primary outcomes

  1. ercentage Reduction in Wound Area

    Wound area will be measured from standardized, calibrated clinical photographs using ImageJ. Percentage reduction will be calculated relative to baseline: \[(baseline wound area - follow-up wound area) / baseline wound area\] × 100. Results will be compared among the three groups over time.

    Time frame: Postoperative days 0, 3, 7, and 14

Secondary outcomes

  1. Wound Healing Score (WHS)

    Clinical wound healing will be assessed using the study's WHS, with a total score ranging from 0 to 9.

    Time frame: Postoperative days 3, 7, and 14

  2. Index of Postoperative Recovery (IPR)

    Postoperative recovery will be assessed using the IPR measure specified in the study protocol.

    Time frame: Postoperative days 3, 7, and 14

  3. Postoperative Pain Intensity

    Pain intensity will be recorded using a 10-cm visual analogue scale (VAS), where 0 indicates no pain and 10 indicates the worst pain.

    Time frame: Postoperative days 1, 3, and 7

  4. Postoperative Analgesic Consumption

    The number of analgesic doses taken by each participant will be recorded in the postoperative medication log.

    Time frame: Postoperative days 1-7

07

Study locations

1 site
  • Cyprus Health and Social Sciences University
    Mórfou, 99750, Cyprus
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2026 to primary completion in Nov 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Oct 27, 2026
StartActual
Oct 5, 2026
Primary completionActual
Nov 3, 2026
CompletionActual
Nov 3, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Primary completion
Nov 2, 2026→Nov 3, 2026 (actual)
Nov 4, 2026
Study completion
Nov 2, 2026→Nov 3, 2026 (actual)
Nov 4, 2026
Registered
First appeared on the registry
Oct 27, 2026
Show all 3 updates
  1. Nov 4, 2026
    Recruiting→Completed
    Primary completion Nov 2, 2026→Nov 3, 2026 (now actual)
    Study completion Nov 2, 2026→Nov 3, 2026 (now actual)
    + 2 other changes: contact details and site details
  2. Oct 28, 2026
    Minor edits only
    + 1 other change: responsible party
  3. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07898163
Lead sponsor
Cyprus Health and Social Sciences University
Responsible party
omran nasab (Principal Investigator, Cyprus Health and Social Sciences University) — Principal investigator
First posted
Oct 27, 2026
Start date
Oct 5, 2026
Primary completion
Nov 3, 2026
Completion
Nov 3, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion